Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.8
4.4
Journals
Cancers
Announcements
cancers-logo

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Announcements

17 December 2024
Over 100 German Universities Partner with MDPI in New National Agreement


More than 100 German universities and research institutions have entered into a national agreement with MDPI. The publication agreement negotiated by ZB MED comes into effect on 1 January 2025 and is valid until the end of 2026. Joining the consortium is still possible until the beginning of 2025. We are delighted by the high level of interest this agreement has already garnered, reflecting the strong demand for accessible and cost-effective open access publishing solutions among German research institutions.

This new cooperation aims to make scientific gold open access publishing more affordable and less administratively burdensome for researchers in Germany. The agreement includes substantial discounts on article processing charges (APCs) for corresponding authors from participating institutions. It offers flexible payment options, including centralized invoicing or individual payment of fees by researchers or their institutions. Additionally, the agreement features a flat-fee model that enables institutions to precisely plan expenses and optimize their library budgets.

"MDPI can look back on over a decade of successful partnerships with German research institutions," says Peter Roth, MDPI Head of Publishing. "The new agreement marks another milestone in the long-standing co-operation between MDPI and the German scientific community. It emphasizes our commitment to developing up-to-date and inventive solutions for the diverse needs of scientific institutions to promote open research for the benefit of researchers."

Petra Labriga, Head of Strategic License Management at ZB MED, highlighted the agreement's significance: "As one of the world's leading Gold OA publishers, MDPI plays a central role in the German publishing landscape. We are particularly pleased that we were able to achieve considerable potential cost savings for scientific institutions and their authors at a national level through our negotiations."

The partnership reflects a common goal of advancing the idea of open access and supporting researchers in making their scientific excellence internationally visible.

"We would like to thank the ZB MED consortium team for their excellent collaboration," added Adrian Stefan Zamfir, MDPI Institutional Partnership Manager for the DACH region. "We are delighted that this agreement will give even more researchers in Germany access to our tried-and-tested and reliable publication platform."

Franziska Fischer (right), Commercial Director at ZB MED, an Peter Roth (left), Head of Publishing at MDPI, celebrate the signing of the new national open access agreement between MDPI and the ZB MED Consortium.

Peter Roth (center) joined ZB MED's Lea Carolina Schindler, Petra Labriga, Franziska Fischer, and Jonathan Lehmann in Cologne, Germany, on 13 December 2024 to sign the agreement.

More Information

  • Conditions and participation opportunities (German): Link
  • Frequently asked questions (German): Link

Contact

About ZB MED

ZB MED - Information Centre for Life Sciences is an infrastructure and research centre for life science information and data. Its aim is to support and strengthen research for people and the environment: from medicine to biodiversity and environmental protection.

The work of ZB MED is orientated towards the strategic guidelines:

  • Research + Networking: We conduct research together with the regionally, nationally, European and globally networked research community.
  • Data science: We enable data analyses and generate new knowledge through research.
  • Access to information: We provide sustainable access to information, literature and data as a central information infrastructure.
  • Open + FAIR: We promote open and reproducible science in line with open science and FAIR principles.
  • Knowledge and skills transfer: We actively impart knowledge, competences and skills.

More information at www.zbmed.de.

About MDPI

Headquartered in Basel, Switzerland, MDPI is one of the world's leading open access publishers with a current portfolio of more than 440 journals in all scientific disciplines. MDPI‘s goal is to advance open science worldwide through greater transparency, efficiency and collaboration. To date, more than 3.7 million researchers have published their results in MDPI journals. The editorial process is overseen by a large network of dedicated reviewers and editors and supported by more than 6500 MDPI employees. MDPI currently works with over 800 academic institutions and 180 scientific societies worldwide, which benefit from a wide range of MDPI services and products.

17 December 2024
Meet Us at the AACR Annual Meeting 2025, 25–30 April 2025, Chicago, IL, USA


The AACR Annual Meeting is the critical driver of progress against cancer, the place where scientists, clinicians, other healthcare professionals, survivors, patients, and advocates gather to share and discuss the latest breakthroughs. From population science and prevention to cancer biology, translational and clinical studies, and survivorship as well as advocacy, the AACR Annual Meeting showcases cutting-edge cancer science and medicine.

The following MDPI journals will be represented:

If you are attending this conference, please feel free to start an online conversation with us. Our delegates look forward to meeting you in person at booth #2819 at the conference and answering any questions that you may have. For more information about the conference, please visit the following link: https://www.aacr.org/meeting/aacr-annual-meeting-2025/.

17 December 2024
Article Layout and Template Revised for Future Volumes

We are pleased to announce a series of updates to our template, aimed at improving the readability and overall aesthetics of our publications. These changes have been meticulously designed to enhance the user experience and ensure consistency across all our publications. The updated template will be available for download from the Instructions for Authors page.

The following updates will be applied to articles published in the 2025 volumes, starting on 24 December 2024:

  • Main text: The line spacing has been increased to improve the readability of publications;
  • Header and footer: The link to the journal website will be removed, as a hyperlink has been integrated into the journal logo. Additionally, the DOI link will be moved from the left-hand side to the right-hand side, and both the header and footer will be slightly raised to achieve a better balance;
  • Left information bar: The information provided here has been rearranged for better organization; the CC-BY logo will be removed;
  • Font size: The font size used for the abstract, keywords, and first-level headings will be increased.

Furthermore, MDPI journals will continue to use article numbers. This approach enables us to maintain a rapid and efficient production process by being able to define pagination as soon as a paper is accepted.

We hope that the new version of the template will provide users with a better experience and make the process more convenient.

Please contact production@mdpi.com if you have any questions or suggestions.

13 December 2024
MDPI’s Open Access Insights: Connecting with Authors at the Kidney Cancer Association Conference in Louisville, Kentucky, USA



Dr. Andy Tran (left) and Dr. Zach Churcher (right) representing for MDPI Canada at the KCA Conference in Kentucky

MDPI recently played a pivotal role in the inaugural meeting of the Kidney Cancer Association’s (KCA) Mentorship Academy, which took place on 6 November 2024, in Louisville, Kentucky, USA, ahead of the 2024 IKCS: North America meeting. Located in the Omni Louisville hotel, this event brought together six mentees, each considered a rising star in kidney cancer research and clinical practice, along with a distinguished group of mentors, to launch a year-long program designed to shape the next generation of kidney cancer experts. The mentorship program aims to provide mentees with guidance, support, and networking opportunities to foster their careers in research, clinical trials, and advocacy.

A highlight of the conference was the session led by MDPI’s own Dr. Zach Churcher and Dr. Andy Tran, as pictured. Dr. Churcher and Dr. Tran shared their expertise on the processes involved in publishing essential and groundbreaking research such as that on kidney cancer in open access journals, emphasizing the strategies they have used to increase the visibility and impact of their work. The session underscored the importance of open access publishing as a tool for quickly disseminating research across the globe, enabling greater collaboration within and the progression of the kidney cancer research community.

Additionally, their session covered the specifics of the academic publishing process within the open access space, emphasizing MDPI's thorough and efficient model, and providing insights into the complexities of publishing in academic journals. Their presentation was interactive, prompting valuable discussions which we are sure made a lasting impression on the attendees. The presentation was praised by other attendees

Dr. Zach Churcher presenting on behalf of MDPI for Kidney Cancer Association

Dr. Andy Tran presenting on behalf of MDPI for Kidney Cancer Association


Dr. Andy Tran showcasing support with KCA promotional props

Dr. Zach Churcher showcasing support with KCA promotional props

as setting the tone for the rest of the session and effectively and seamlessly guiding attendees through the academic publishing process. Many of the scholars present also spoke highly of their personal experiences publishing with MDPI. One scholar shared with the group that their most impactful work was a 45-page review article submitted to MDPI’s Cancers journal. They emphasized that MDPI provided them with the freedom to publish their extensive work without the restrictions often imposed by other publishers. They concluded by emphasizing that their experience with MDPI was seamless and efficient, and benefited from stellar communication throughout.

MDPI’s participation in this event is a testament to our company’s commitment to supporting the development of emerging researchers. By providing training on the publishing process and offering valuable resources for authors, MDPI is empowering the next generation of kidney cancer researchers to share their groundbreaking work with the world. The knowledge shared during this session will undoubtedly help these mentees to succeed in their academic careers and contribute to the continued advancement of kidney cancer research.

As the KCA Mentorship Academy progresses, MDPI’s ongoing involvement will play a critical role in shaping the future of kidney cancer research and clinical care. With continued mentorship and support, these mentees will gain the skills, knowledge, and networks necessary to become leaders in their field, advancing research, improving patient outcomes, and driving innovation in kidney cancer treatment.

To conclude, the inaugural meeting of the KCA Mentorship Academy highlighted MDPI's significant contribution to the advancement of kidney cancer research and the development of the next generation of clinical experts. Through insightful authorship training sessions and interactive discussions, MDPI not only facilitated the dissemination of key publishing strategies but also reinforced the importance of open access publishing in promoting global collaboration and accelerating research. The positive feedback we received from participants further underscores MDPI’s role in empowering researchers to contribute meaningful advancements to their fields. As the Kidney Cancer Association continues its research-based initiatives, MDPI’s ongoing support and expertise will undoubtedly remain a valuable resource for all involved in shaping the future of kidney cancer research. We want to say a special thank you to Dr. Zach Churcher and Dr. Andy Tran for proudly representing MDPI at this year’s Kidney Cancer Association’s author conference. An additional heartfelt thank you also goes out to all of the speakers, presenters, and attendees who made this conference a success.

Please do not hesitate to contact us at toronto@mdpi.com if you are based in North America and are interested in holding an author training session with MDPI.

6 December 2024
MDPI INSIGHTS: The CEO's Letter #18 - MDPI UK, Basel Job Fair, CETEF'24

Welcome to the MDPI Insights: The CEO's Letter.

In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.


Opening Thoughts

MDPI’s First UK Summit Held in Manchester

On 29 November, we hosted our first annual MDPI UK Summit, bringing together over 30 Chief Editors and Editorial Board Members (EBMs) to discuss MDPI’s mission, achievements, and collaborations in the UK.

Throughout the day we had talks from several members of MDPI, roundtable discussions on the peer-review process and upholding research integrity, and an engaging presentation from the Editor-in-Chief (EiC) of MDPI journal Mathematics, Francisco Chiclana, about his involvement with the Research Excellence Framework.

“This was a great first summit for MDPI UK and received excellent feedback”

 In the following I highlight some of the sessions and the discussion topics covered in each session.

Session 1: Opening Speech and Introduction to MDPI

I shared an overview of MDPI’s mission, achievements, and commitment to quality. The Q&A touched on key topics such as perception and reputation management, expanding our arts and humanities portfolio, and funding challenges for open access (OA) in the UK.

A takeaway from this session was that in 2025, we will circulate a mini annual report to all editors, helping them understand MDPI’s mission and achievements beyond the context of their specific journals.

Session 2: MDPI and the Research Excellence Framework (REF)
Prof. Francisco Chiclana (EiC of Mathematics) highlighted MDPI’s role in REF, its purpose, and future directions.

Session 3: Editorial Process, Ethics, and Research Integrity
Dr. Giulia Stefenelli presented on the various editorial roles and responsibilities, quality metrics, and procedures for dealing with misconduct. The Q&A centred on AI in publishing, institutional roles in research integrity, and better data management practices.

Session 4: Institutional Open Access Program (IOAP)
Becky Castellon presented on IOAP benefits, including MDPI’s partnership with JISC, which includes more than 60 UK institutions, and highlighted the advantages of pure OA over transformative agreements.

Session 5: Round Table Discussion
Colleagues from our MDPI Manchester office Jaime Anderson and Dr. Michael O’Sullivan, along with colleagues from our Basel office Damaris Critchlow and Giulia Stefenelli, discussed innovations in peer review, challenges in maintaining scientific integrity, and future solutions.

Session 6: MDPI PR and the Voice of the Customer
I recapped our customer satisfaction drivers, including speed and editorial support. I also spoke about tackling misinformation about OA and MDPI in general, and outlined a way forward for us all to participate in advocating for open science.

This was a great first summit for MDPI UK and received excellent feedback from our EiCs, SEiCs, and EBMs. A BIG thank-you to our Manchester team (pictured below) and everyone else involved in organizing this event. Their hard work and dedication are much appreciated!

Impactful Research

MDPI and UK Publications

The UK is an important market for MDPI, ranking ninth in total submissions to MDPI and eighth in total MDPI publications, with over 72,200 publications to date. As at October 2024, there were more than 3,600 EBMs from the UK, 48% of whom have an H-index above 26. We also have 46 EiCs, and 63 SEiCs in the UK, some of whom joined us in Manchester for the UK Summit.

The UK is a strong advocate of OA publishing, with nearly three quarters of all articles in 2023 published on open access platforms. The country enjoys a large academic market, producing high-quality papers, and is home to some of the world’s top universities. Among MDPI’s 825 IOAP agreements, over 60 of these are in the UK, facilitated through our partnership with JISC.

“The UK is a strong advocate of OA publishing”

 Visit to MDPI’s Manchester Office

Last week, I visited our Manchester office to see the expanding office space, connect with our staff, and present at the MDPI UK Summit held in Manchester.

Throughout the day, I met with various teams to better understand their work and discuss their future development plans in greater depth. Hearing from group leads about the progress we have made and the challenges we face offered many valuable insights. I also had the chance to connect personally with members of the content team. It’s great to see how this young and ambitious team is coming together.

I also took the opportunity to address the entire office about the role of MDPI UK within the wider company. During this session, I answered questions about growth and public relations initiatives. Giulia Stefenelli joined us to address questions about the role of AI in MDPI’s future.

Jaime Anderson (Office Manager) and the Manchester team have done a great job of growing the office since its establishment in 2019. Today, it has around 150 staff members across various departments, including English editing, editorial services, marketing and communications, and IOAP. The team is highly active in local marketing initiatives, such as author training sessions, scholar visits, and conferences.

For more information and updates on our Manchester office, follow MDPI UK on LinkedIn.

Inside MDPI

Basel Job Fair

In November, the HR team from our Basel office connected with over 300 young professionals at the Basel Job Fair 2024. This is my biased opinion, of course, but we had the best branded booth and merchandise, which drew a lot of attention from young talent wanting to learn about current and future job opportunities at MDPI.

Our HR team also helped review CVs on the spot, providing advice on how to improve them and making a positive impression on the future workforce in Basel.

This is a reminder that MDPI is not only focused on supporting young researchers but that we also recruit and develop young talent. We have seen MDPI HR do this really well throughout all of our offices, from Asia Pacific to Europe and North America.

HR plays an important role in our growing company, helping us meet our recruitment targets as well as providing support for local teams, guidance on management and best practices, a safe space for employees, and brand recognition for MDPI, among many other things.

“MDPI is not only focused on supporting young researchers: we also recruit and develop young talent”

This is a quick appreciation post to all HR staff working to support MDPI and our colleagues, cultivating talent and supporting careers at every stage. Thanks HR staff, keep up the great work!

Coming Together for Science

Pharmaceuticals 2024 – Recent Advances in Pharmaceutical Sciences Towards a Healthy Life (The 20th Anniversary)

I am pleased to share that the Pharmaceuticals 2024 – Recent Advances in Pharmaceutical Sciences Towards a Healthy Life took place from 27 to 29 November 2024 in Barcelona, Spain. It was chaired by Prof. Dr. Amelia Pilar Rauter from the Universidade de Lisboa, Portugal; Dr. Alfredo Berzal Herranz from Instituto de Parasitología y Biomedicina López-Neyra (IPBLN) CSIC, Spain; and Prof. Dr. Mary Jane Meegan from Trinity College Dublin, Ireland.

The conference took place in Casa Convalescència, a part of the Sant Pau Art Nouveau Site. The three-day event included three plenary sessions and eight invited speakers, from eight countries, and 29 selected talks. Of the presentations on site, there were 32 posters and 29 oral presentations.

The main goal of the ‘Pharmaceuticals 2024’ international conference was to cover the newest technologies and research areas including medicinal chemistry, natural products, organic synthesis, radiopharmaceuticals, pharmacology, toxicology, and biomolecular and glycosciences, in a meeting that brought together experts to present their latest findings on combatting infection, inflammation, pain, and neurodegeneration, to mention just a few of the topics that were discussed.

“The main goal of ‘Pharmaceuticals 2024’ was to cover the newest technologies and research areas”

20th Anniversary of Pharmaceuticals

The year 2024 marks the 20th anniversary of Pharmaceuticals – a journal dedicated to medicinal chemistry and related drug sciences, which is published monthly online by MDPI. To honour this milestone, we are reflecting on our past accomplishments and embarking on an exciting new chapter. This celebration is also one of the reasons why we organized the conference Pharmaceuticals 2024. With an Impact Factor of 4.3 and a CiteScore of 6.1, the journal is covered in Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus/SciFinder, and other databases. Pharmaceuticals has published over 6,000 papers from more than 37,000 authors. More than 10,000 reviewers have reviewed for it at least once.

20th Anniversary of Pharmaceuticals: The Video

This video captures the experiences of the conference chairs, honorary guests and committee members of the conference.

 

Thank you to our partnering societies

A special thank-you is due to our partnering societies the Spanish Society Of Medicinal Chemistry (SEQT) and the Spanish Society For Biochemistry And Molecular Biology (SEBBM) for their support of the Pharmaceuticals 2024 conference. I am also pleased to report that we presented two awards, sponsored by the journal Pharmaceuticals, including the Best Presentation Award and the Best Oral Presentation Award, recognizing the contributions of our participants.

Closing Thoughts

Presenting at the 4th Central European Technology Forum

I visited Krakow, Poland in November to participate in the 4th Central European Technology Forum (CETEF’24), which took place on 18 and 19 November.

CETEF is an international conference that has been jointly organized since 2014 by the Polish Chamber of Commerce for Advanced Technologies (IZTECH) and the Polish Federation of Engineering Associations, with the support of the European Parliament and the European Commission, in cooperation with universities, research institutes and the high-tech industry. The 2024 event focused on presentation to advance the European science and technology agenda for 2025–2030.

MDPI participated as a key publishing sponsor. We had an exhibition booth and held two key presentations during the conference. On Monday, I presented MDPI’s vision, purpose, and achievements.

On Tuesday, Dr. Giulia Stefenelli shared how MDPI supports advancements in high technology and energy transition, highlighting our portfolio, services, tools and initiatives for promoting progress and interdisciplinary collaboration.

We received positive feedback from scientists and government representatives in attendance.

A big thank-you goes to our colleagues from the Krakow office for their support in organizing our participation and managing the MDPI booth.

Special thanks are owing to Weronika Gorka-Kumik, Igor Matic, Vincent Di, Agnieszka Rydz, Ksenia Shubenkova, Anna Krakowka and Klaudia Kasprowicz.

Below is a photo with the President of the Polish Chamber of Commerce conference (centre), along with MDPI colleagues Giulia Stefenelli, Weronika Gorka-Kumik, and Igor Matic (left to right).

“This year’s event focused on ideas and proposals to advance the European science and technology agenda for 2025–2030”

Stefan Tochev
Chief Executive Officer
MDPI AG

5 December 2024
Cancers | Lung Cancer Awareness Month


November is Lung Cancer Awareness Month, and there are various global activities aiming to highlight and increase the awareness of lung cancer for research support and development. We would like to take this opportunity to extend our appreciation to all the researchers who have contributed to the fight against this disease. In particular, we would like to share some of the high-quality and innovative research findings in the field of lung cancer, which were published in Cancers (ISSN: 2072-6694). We hope this announcement will provide useful information for this field. The list of relevant papers can be seen below.

“Antibody–Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence”
by Pooja Gogia, Hamza Ashraf, Sidharth Bhasin and Yiqing Xu
Cancers 2023, 15(15), 3886; https://doi.org/10.3390/cancers15153886
Available online: https://www.mdpi.com/2072-6694/15/15/3886

“Artificial Intelligence-Based Treatment Decisions: A New Era for NSCLC”
by Oraianthi Fiste, Ioannis Gkiozos , Andriani Charpidou and Nikolaos K. Syrigos
Cancers 2024, 16(4), 831; https://doi.org/10.3390/cancers16040831
Available online: https://www.mdpi.com/2072-6694/16/4/831

“The Matrix Stiffness Coordinates the Cell Proliferation and PD-L1 Expression via YAP in Lung Adenocarcinoma”
by Yeonhee Park, Dahye Lee, Jeong Eun Lee, Hee Sun Park, Sung Soo Jung, Dongil Park, Da Hyun Kang, Song-I Lee, Seong-Dae Woo and Chaeuk Chung
Cancers 2024, 16(3), 598; https://doi.org/10.3390/cancers16030598
Available online: https://www.mdpi.com/2072-6694/16/3/598

“ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung Cancer”
by Aakash Desai, Tadana A. Vázquez, Keishla M. Arce, Marcelo Corassa, Philip C. Mack, Jhanelle E. Gray and Bruna Pellini
Cancers 2024, 16(5), 940; https://doi.org/10.3390/cancers16050940
Available online: https://www.mdpi.com/2072-6694/16/5/940

“The Diagnostic Value of ACSL1, ACSL4, and ACSL5 and the Clinical Potential of an ACSL Inhibitor in Non-Small-Cell Lung Cancer”
by Yunxia Ma, Miljana Nenkov, Alexander Berndt, Mohamed Abubrig, Martin Schmidt, Tim Sandhaus, Otmar Huber , Joachim H. Clement, Susanne M. Lang, Yuan Chen et al.
Cancers 2024, 16(6), 1170; https://doi.org/10.3390/cancers16061170
Available online: https://www.mdpi.com/2072-6694/16/6/1170

“Influencing Factors on the Quality of Lymph Node Dissection for Stage IA Non-Small Cell Lung Cancer: A Retrospective Nationwide Cohort Study”
by Piotr Gabryel, Piotr Skrzypczak, Magdalena Roszak, Alessio Campisi, Dominika Zielinska, Maciej Bryl, Katarzyna Stencel and Cezary Piwkowski
Cancers 2024, 16(2), 346; https://doi.org/10.3390/cancers16020346
Available online: https://www.mdpi.com/2072-6694/16/2/346

“Is Immunotherapy Beneficial in Patients with Oncogene-Addicted Non-Small Cell Lung Cancers? A Narrative Review”
by David John McMahon, Ronan McLaughlin and Jarushka Naidoo
Cancers 2024, 16(3), 527; https://doi.org/10.3390/cancers16030527
Available online: https://www.mdpi.com/2072-6694/16/3/527

“ATOH1, TFAP2B, and CEACAM6 as Immunohistochemical Markers to Distinguish Merkel Cell Carcinoma and Small Cell Lung Cancer”
by Serena M. Vilasi, Jannett Nguyen, Catherine J. Wang, Lingling Miao, Kenneth Daily, Mary Eid, Joon Seon Song, Hong Jiang, Kris Ylaya, Klaus J. Busam et al.
Cancers 2024, 16(4), 788; https://doi.org/10.3390/cancers16040788
Available online: https://www.mdpi.com/2072-6694/16/4/788

“Social and Biological Determinants in Lung Cancer Disparity”
by Briana A. Brock, Hina Mir, Eric L. Flenaugh, Gabriela Oprea-Ilies, Rajesh Singh and Shailesh Singh
Cancers 2024, 16(3), 612; https://doi.org/10.3390/cancers16030612
Available online: https://www.mdpi.com/2072-6694/16/3/612

“Optimal Treatment Strategy for Oligo-Recurrence Lung Cancer Patients with Driver Mutations”
by Taimei Tachibana, Yosuke Matsuura, Hironori Ninomiya, Junji Ichinose, Masayuki Nakao, Sakae Okumura, Makoto Nishio, Norihiko Ikeda and Mingyon Mun
Cancers 2024, 16(2), 464; https://doi.org/10.3390/cancers16020464
Available online: https://www.mdpi.com/2072-6694/16/2/464

You are welcome to submit relevant papers to the journal Cancers.

Cancers Editorial Office

4 December 2024
685 MDPI Editors Named Highly Cited Researchers in 2024


We extend our heartfelt congratulations to the 685 Editorial Board Members of our journals – from 39 different countries and territories – who have been recognized as Highly Cited Researchers for 2024 by Clarivate. This distinction highlights their exceptional scientific achievements and significant contributions, which transcend academic boundaries to advance global knowledge, sustainability, security, and well-being.

Clarivate's annual Highly Cited Researcher™ list identifies the most influential scientists of the past decade, whose work has had a profound and widespread impact across various scientific and social science disciplines. Their impactful papers rank among the top 1% by citations in one or more of the 21 fields analyzed within the "Essential Science Indicators," marking them as leaders in their respective domains.

"Highly Cited Researchers have demonstrated significant and broad influence in their field(s) of research," according to Clarivate. In 2024, a total of 6,886 Highly Cited Researcher designations were awarded to 6,636 individuals.

The following is a list of MDPI's Editorial Board Members named Highly Cited Researchers in 2024. We congratulate them for their achievement and their contributions to advancing knowledge in their respective fields.

Abate, Antonio
Abbate, Antonio
Aguilera, Ruth V.
Ahmed, Warish
Ahn, Myung-Ju
Ambretti, Simone
Anasori, Babak
Andersson, Dan I.
Annabi, Nasim
Antinori, Spinello
Arbabi, Amir
Ariga, Katsuhiko
Astruc, Didier
Bajpai, Vivek K.
Balaj, Leonora
Balsamo, Gianpaolo
Bando, Yoshio
Banks, William A.
Barnes, Peter J.
Barnholtz-Sloan, Jill S.
Barros, Lillian
Bashir, Ali Kashif
Basit, Abdul W.
Bassetti, Matteo
Batley, Jacqueline
Battino, Maurizio
Benediktsson, Jon Atli
Bjarnsholt, Thomas
Blaschke, Thomas
Blay, Jean-Yves
Blumwald, Eduardo
Blunt, John W.
Bonomo, Robert A.
Bourke, Paula
Boyd, Robert W.
Boyer, Cyrille
Bruyere, Olivier
Bu, Wenbo
Bush, Ashley I.
Byrd, John C.
Cabeza, Luisa F.
Cai, Baoping
Cai, Lei
Cai, Xingjuan
Cambria, Erik
Cao, Guozhong
Cao, Xingzhong
Carvalho, Andre F.
Chan, Jasper Fuk-Woo
Chan, Timothy A.
Chao, Dongliang
Chen, Bin
Chen, Bo
Chen, Chaoji
Chen, Fahu
Chen, Hualan
Chen, Jun
Chen, Kunsong
Chen, Lidong
Chen, Lingxin
Chen, Mou
Chen, Peng
Chen, Qianwang
Chen, Shaowei
Chen, Shuai
Chen, Shuangming
Chen, Xiangyu
Chen, Xiao
Chen, Xiaobo
Chen, Xu
Chen, Yimin
Chen, Yulin
Cheng, Gong
Cheng, Huanyu
Cheng, Laifei
Cheng, Qiang
Chiclana, Francisco
Choi, Wonyong
Choi, Young Hae
Chowdhary, Anuradha
Clevers, Hans
Collins, Maurice N.
Cortes, Javier
Cortes, Jorge
Cottin, Vincent
Creutzig, Felix
Crommie, Michael F.
Cuadrado, Antonio
Cui, Yi
Dai, Hongjie
Dai, Shifeng
Daiber, Andreas
Davis, Steven J.
Davis, Thomas P.
Dawson, Ted M.
de Vries, Rory D.
de Vries, Wim
Deng, Xiangzheng
Desneux, Nicolas
Ding, Aijun
Ding, Jianxun
Dokmeci, Mehmet Remzi
Dolgui, Alexandre
Dou, Shi Xue
Dragicevic, Tomislav
Du, Bo
Du, Qian
Du, Yonghua
Duan, Xidong
Dufresne, Alain
Dummer, Reinhard
Ebi, Kristie L.
Edwards, David
Enjuanes, Luis
Fabbro, Doriano
Facchetti, Antonio
Fan, Junliang
Fan, Kelong
Fan, Xiulin
Fang, Chuanglin
Fang, Jingyun
Fang, Yongjin
Fasano, Alessio
Felser, Claudia
Feng, Xuning
Ferdinandy, Péter
Filippi, Massimo
Flavian, Carlos
Fortino, Giancarlo
Fowler, Michael
Franceschi, Claudio
Fu, Gengtao
Fu, Yongshuo
Fujita, Hamido
Gagaoua, Mohammed
Gai, Francesco
Gaisford, Simon
Galano, Annia
Galluzzi, Lorenzo
Galvano, Fabio
Gao, Huijun
Gao, Huile
Gao, Junkuo
Gao, Peng
Garbe, Claus
Garcia, Hermenegildo
Gasbarrini, Antonio
Genevet, Patrice
Geng, Yong
Gerdts, Gunnar
Geschwind, Daniel H.
Ghaffari, Roozbeh
Ghamisi, Pedram
Giampieri, Francesca
Gobbetti, Marco
Godos, Justyna
Gogotsi, Yury
Golding, Nick
Gong, Jinlong
Gong, Peng
Gotor, Cecilia
Govindan, Kannan
Grancini, Giulia
Grant, William B.
Graus, Francesc
Green, Douglas R.
Greenberg, Dan
Grigoriev, Igor
Grosso, Giuseppe
Gu, Zhanjun
Guan, Cao
Gueimonde, Miguel
Gui, Guan
Guo, Hengyu
Guo, Jianping
Guo, Jinghua
Guo, Song
Guo, Zaiping
Gutzmer, Ralf
Győrffy, Balázs
Haase, Dagmar
Hagger, Martin S.
Han, Buxing
Han, Fudong
Han, Heesup
Hanes, Justin
Hao, Junnan
He, Bao-Jie
He, Chi
He, Debiao
He, Hongwen
He, Jiaqing
He, Jr-Hau
He, Ping
He, Xiangming
He, Xijun
He, Zhili
Heinrich, Michael
Heneka, Michael Thomas
Henry, Brandon Michael
Herrera, Francisco
Herrera-Estrella, Luis
Hilal, Nidal
Hong, Danfeng
Hossain, Ekram
Hu, Enyuan
Hu, Jin-Song
Hu, Wenbin
Hu, Xiaosong
Huang, Bo
Huang, Haitao
Huang, Hongwei
Huang, Jianping
Huang, Qing
Huang, Yan
Huang, Yu
Hubacek, Klaus
Hwang, Jinsoo
Italiano, Antoine
Iwata, Hiroji
Izzo, Angelo A.
Jaiswal, Amit K.
Jankovic, Joseph
Jelezko, Fedor
Jeon, Byong-Hun
Ji, Jian
Ji, Xiaobo
Ji, Xiaoyuan
Jiang, Lei

Jiang, Lianzhou
Jiang, Shibo
Jiang, Yuji
Jiang, Yuyan
Jiang, Zhongyi
Jiao, Licheng
Jin, Hailing
Jin, Yuanxiang
Jin, Zhengyu
Jin, Zhong
Jing, Qingshen
Kalantar-zadeh, Kourosh
Kamal, Mohammad Amjad
Kaneti, Yusuf Valentino
Kang, Xudong
Kang, Zhenhui
Karagiannidis, George K.
Karki, Rajendra
Karniadakis, George Em
Kataoka, Kazunori
Katritch, Vsevolod
Kawi, Sibudjing
Kepp, Oliver
Khademhosseini, Ali
Kiessling, Fabian
Kim, Jong Seung
Kim, Jong-Hoon
Kim, Sung-Bae
Kim, Sunghwan
Kirkwood, John M.
Kivshar, Yuri
Klein, Christian
Klenk, Hans-Peter
Koh, Lenny
Kong, Baohua
Krause, Robert
Kroemer, Guido
Kudo, Masatoshi
Kumar, Anil
Kumar, Prashant
Kumar, Sudhir
Kurths, Juergen
Kurzrock, Razelle
Kyrpides, Nikos C.
La Vecchia, Carlo
Lam, Tommy Tsan-Yuk
Lan, Ke
Lancellotti, Patrizio
Landi, Francesco
Landi, Marco
Lavie, Carl J.
Lee, Chengkuo
Lee, Jin-Wook
Lee, Pooi See
Lehmann, Johannes
Lei, Yaguo
Li, Bing
Li, Chunzhong
Li, Dawei
Li, Dongfang
Li, Dongsheng
Li, Jingchao
Li, Jing-Feng
Li, Jinghong
Li, Linlin
Li, Meng
Li, Neng
Li, Ning
Li, Shutao
Li, Xiang
Li, Xuecao
Li, Yaping
Li, Yat
Li, Yong
Li, Yonghui
Li, Yurui
Liang, Hanfeng
Liang, Shuquan
Lin, Jun
Lin, Yi
Lin, Yuehe
Lippi, Giuseppe
Liu, Chengmei
Liu, Feng
Liu, Hong
Liu, Hongyu
Liu, Jian-Kui (Jack)
Liu, Meilin
Liu, Min
Liu, Shujuan
Liu, Xianhu
Liu, Xiaoping
Liu, Xuejun
Liu, Yu
Loh, Xian Jun
Long, Guankui
Long, Hualou
Long, Ying
Lu, Jianquan
Lu, Junling
Lu, Nanshu
Lu, Shun
Lu, Yingying
Lugato, Emanuele
Lund, Henrik
Luo, Jie
Luo, Jingshan
Luo, Yangchao
Luo, Zisheng
Lutolf, Matthias P.
Lv, Wei
Lyons, Timothy W.
Ma, Chao
Ma, Tianyi
Ma, Yanming
Mahmood, Nasir
Mahmoudi, Morteza
Mandalà, Mario
Mao, Jianfeng
Mao, Like
Martin-Belloso, Olga
Martinez, Luis
Mateos, Maria Victoria
Mathiesen, Brian Vad
Matyjaszewski, Krzysztof
McCauley, Darren
Mei, Lin
Melenhorst, Jan Joseph
Melero, Ignacio
Meyerholz, David K.
Miao, Song
Miroshnichenko, Andrey E.
Mittler, Ron
Montagne, Axel
Moreau, Philippe
Mu, Shichun
Muhammad, Khan
Mulligan, Mark J.
Mumtaz, Shahid
Nauen, Ralf
Nemeroff, Charles B.
Niaura, Raymond S.
Nussinov, Ruth
Oganov, Artem R.
Oh, Deog Hwan
O'Reilly, Eileen M.
Ouyang, Minggao
Ozcan, Aydogan
Pacher, Pal
Pan, Anlian
Pan, Anqiang
Pan, Caofeng
Pan, Genxing
Pan, Xiaoqing
Parati, Gianfranco
Peng, Qiang
Peng, Qing
Peng, Shushi
Perlin, David S.
Perlman, Stanley
Petruzzelli, Antonio Messeni
Peyrin-Biroulet, Laurent
Pitt, Bertram
Pöhlmann, Stefan
Polasky, Stephen
Pommier, Yves
Poor, H. Vincent
Portincasa, Piero
Potenza, Marc N.
Prinsep, Michele R.
Pu, Hongbin
Pu, Kanyi
Putnik, Predrag
Qi, Jianping
Qiang, Yujie
Qin, Yuanwei
Qiu, Jieshan
Qu, Xiaogang
Ragauskas, Arthur J.
Ramkissoon, Haywantee
Ran, Jingrun
Rao, Zhonghao
Ren, Jinsong
Rengel, Zed
Rezania, Shahabaldin
Rho, Junsuk
Riahi, Keywan
Ribeiro-Soriano, Domingo
Richardson, Paul G.
Rignot, Eric
Robert, Caroline
Rocca, Maria A.
Rodriguez-Manas, Leocadio
Rojas, Orlando J.
Rojo, Teofilo
Rossolini, Gian Maria
Saad, Walid
Saif, Linda J.
Saliba, Michael
Sander, Chris
Saso, Luciano
Scaldaferri, Franco
Schafer, Alexandra
Schatzberg, Alan F.
Schwab, Matthias
Scolyer, Richard A.
Scorrano, Luca
Scott, Stuart A.
Serruys, Patrick W.
Shao, Minhua
Shao, Shuai
Shao, Zongping
Shen, Guozhen
Shen, Liyin
Shen, Zexiang
Shi, Kai
Shi, Pei-Yong
Shi, Peng
Shi, Yi
Shin, Hyeon Suk
Shin, Su Ryon
Siano, Pierluigi
Simões, Manuel
Simpson, Richard J.
Sing, Swee Leong
Singh, Vijay P.
Skouta, Rachid
Smagghe, Guy

Song, Jibin
Song, Yanlin
Sood, Anil K.
Souto, Eliana B.
Speiser, Daniel E.
Stadler, Marc
Stephanopoulos, Gregory
Sternberg, Cora N.
Stoumpos, Constantinos C.
Su, Chao
Su, Dong
Sun, Cuixia
Sun, Fengchun
Sun, Guangyong
Sun, Jian
Sun, Litao
Sun, Xian
Sun, Zaicheng
Sun, Zhipei
Sureda, Antoni
Svenning, Jens-Christian
Tan, Chaoliang
Tang, Ben Zhong
Tang, Chuan-He
Tang, Chuyang
Tang, Dianping
Tang, Yawen
Tang, Yongbing
Tanzi, Rudolph E.
Tao, Yang
Teichmann, Sarah
Telenti, Amalio
Tian, He
Tian, He
Timsit, Jean-Francois
Tohge, Takayuki
Tran, Lam-Son Phan
Tress, Wolfgang
Trivedi, Pankaj
Tsao, Rong
Tsuda, Kenichi
Tukker, Arnold
Tung, Chen-Ho
van der Werf, Guido
Van Mierlo, Joeri
Vandenbroucke, Roosmarijn E.
Varsani, Arvind
Vatanen, Tommi
Verbeke, Kristin
Verpoorte, Robert
Vieta, Eduard
Vincent, Jean-Louis
Vinu, Ajayan
Vita, Antonio
Wagner, Wolfgang
Walters, William
Wan, Jiafu
Wanek, Wolfgang
Wang, Chunsheng
Wang, Dawei
Wang, Dongdong
Wang, Fang
Wang, Fayuan
Wang, Gongming
Wang, Guoxiu
Wang, Haihui
Wang, Huanting
Wang, John
Wang, Joseph
Wang, Lianzhou
Wang, Lihui
Wang, Qi
Wang, Qingsong
Wang, Rui
Wang, Shaojian
Wang, Sibo
Wang, Tao
Wang, Wenguan
Wang, Yanbo
Wang, Yong
Wang, Yonghong
Wang, Yu
Wang, Zhiyu
Wang, Zhong Lin
Wang, Zhongrui
Wang, Zifa
Wang, Ziyun
Wang, Zuankai
Wedzicha, Jadwiga
Wei, Haotong
Wei, Leyi
Wei, Mingyang
Wei, Zhixiang
Wei, Zhongbao
Weiskirchen, Ralf
Weissleder, Ralph
Wen, Guanghui
Wenwu, Yu
Wesemael, Bas van
Witlox, Frank
Wu, Di
Wu, Haijun
Wu, Hao
Wu, Hao Bin
Wu, Jianzhong
Wu, Lifeng
Wu, Qinglin
Wu, Shuilin
Wu, Tom
Wu, Yongning
Wu, Yongzhen
Wu, Yuping
Wu, Zheng-Guang
Wu, Zhong-Shuai
Xia, Jianguo (Jeff)
Xia, Xinhui
Xia, Xiufang
Xia, Yongyao
Xia, Zhiguo
Xiang, Quanjun
Xin, Sen
Xing, Wei
Xiong, Rui
Xu, Jianping
Xu, Li Da
Xu, Ping
Xu, Wu
Xu, Xiaomin
Xu, Xiaopeng
Xu, Zhenjiang Zech
Yan, Chong
Yan, Jun
Yan, Qingyu
Yang, Chenguang
Yang, Hongshun
Yang, Jianping
Yang, Shihe
Yang, Wei
Yang, Xin-She
Yang, Xinsong
Yang, Yongqing
Yang, Yun-Gui
Yao, Yonggang
Ye, Jun
Yin, Shen
Yin, Shou-Wei
Yin, Yulong
Yin, Zongyou
Yokoya, Naoto
Young, Allan H.
Yu, Bin
Yu, Guihua
Yu, Minghao
Yu, Shu-Hong
Yuan, Qiangqiang
Yuan, Yifei
Yue, Dong
Yue, Wenze
Zeadally, Sherali
Zeng, Xiaoxiong
Zhai, Guangtao
Zhai, Tianyou
Zhang, Anna Jinxia
Zhang, Bin
Zhang, Fang
Zhang, Fucang
Zhang, Fusuo
Zhang, Guangyu
Zhang, Guoqing
Zhang, Hengjie
Zhang, Jian
Zhang, Kai
Zhang, Lefei
Zhang, Liangpei
Zhang, Linqi
Zhang, Qiaobao
Zhang, Shanqing
Zhang, Shaoqing
Zhang, Shujun
Zhang, Tierui
Zhang, Wenjun
Zhang, Xian-Ming
Zhang, Xiaodong
Zhang, Xiaoling
Zhang, Yi-Zhou
Zhang, Yong-Wei
Zhang, Yu Shrike
Zhang, Yu-Dong
Zhang, Yue-Jun
Zhang, Yuelin
Zhang, Zhien
Zhao, Biao
Zhao, Guochun
Zhao, Jie
Zhao, Kangning
Zhao, Li-Dong
Zhao, Qing
Zhao, Yi
Zhavoronkov, Alex
Zheng, Hao
Zheng, Weitao
Zheng, Yufeng
Zhong, Cheng
Zhong, Yanfei
Zhou, Di
Zhou, Feng
Zhou, Jizhong
Zhou, Kun
Zhou, Lei
Zhou, Liang
Zhou, Peng
Zhou, Weijia
Zhou, Weiqi
Zhou, Yanhong
Zhou, Yuyu
Zhou, Zhigang
Zhu, Chengzhou
Zhu, Hongwei
Zhu, Junfa
Zhu, Jun-Jie
Zhu, Yongfa
Zhu, Zhe
Zhuang, Xiaodong
Zipfel, Stephan
Zou, Guoqiang
Zou, Ruqiang
Zoulim, Fabien
Zuo, Chao

2 December 2024
Join Us at “MDPI Open Access — Online Author Training Program with City University London”, 3 December 2024

MDPI is pleased to collaborate with City University London, UK, to host an author training session that provides essential insights into MDPI and the world of Open Access publishing. Academic Editors from MDPI will lead the session, focusing on the theme of peer review in academic publishing. Peer review is a fundamental process that not only enhances the quality of individual research but also bolsters the integrity of the wider academic community.

Date: 3 December 2024
Time: 11:00 a.m.–1:00 p.m. (GMT)
Registration link: https://us02web.zoom.us/webinar/register/WN_aYlYqAqrQrqITqYjDbFYmg

Program:

Speaker/Presentation

Time (in GMT)

Opening Speech

11:00 a.m.–11.10 a.m.

Ms. Mary O’Sullivan
Introduction to MDPI and Open Access Publishing

11:10 a.m.–11.30 a.m.

Ms. Bianca Berezoschi Raluca
How to Peer Review a Manuscript + How to Respond to Peer Review Comments

11:30 a.m.–11:50 a.m.

Ms. Mary O’Sullivan
Reasons for Manuscript Rejections

11:50 a.m.–12:10 p.m.

Q&A Session

12:10 p.m.–12:25 p.m.

Closing Speech

12:25 p.m.–12:30 p.m.

MDPI Speakers:

Speaker

Biography


Ms. Mary O'Sullivan

Ms. Mary O'Sullivan obtained her B.Sc. in genetics in 2019 and her M.Sc. in molecular cell biology with bio-innovation in 2020 from University College Cork, Ireland. She started her career at MDPI in January 2023 working within the Editorial Department for the journal Cancers as an Assistant Editor and, following this, a Section Managing Editor. Currently, Ms. O'Sullivan is a Journal Relations Specialist based in the UK office in Manchester.


Ms. Bianca Berezoschi Raluca

Ms. Bianca Berezoschi Raluca holds a master’s degree in clinical psychology from 'Babes-Bolyai' University in Cluj, Romania. She joined MDPI in 2020 and has since undertaken various roles within the editorial department. Currently, she is serving as a Journal Relations Specialist, where she focuses on cultivating strong relationships with scholars, readers, and other stakeholders, overseeing the development and strategic direction of internal and external relations for MDPI journals.

21 November 2024
Cancers | Notable Papers in the Field of Nanomaterials and Cancer Therapy


As all the articles published in Cancers (ISSN: 2072-6694) are open access, you have free and unlimited access to the full text of all articles. We welcome you to read our notable papers in the field of nanomaterials and cancer therapy, which are listed below.

1. “The Promise of Nanoparticles-Based Radiotherapy in Cancer Treatment”
by Munima Haque, Md Salman Shakil and Kazi Mustafa Mahmud
Cancers 2023, 15(6), 1892; https://doi.org/10.3390/cancers15061892
Available online: https://www.mdpi.com/2072-6694/15/6/1892

2. “Evaluation of a Balloon Implant for Simultaneous Magnetic Nanoparticle Hyperthermia and High-Dose-Rate Brachytherapy of Brain Tumor Resection Cavities”
by Shuying Wan, Dario B. Rodrigues, Janet Kwiatkowski, Omaditya Khanna, Kevin D. Judy, Robert C. Goldstein, Marty Overbeek Bloem, Yan Yu, Sophia E. Rooks, Wenyin Shi et al.
Cancers 2023, 15(23), 5683; https://doi.org/10.3390/cancers15235683
Available online: https://www.mdpi.com/2072-6694/15/23/5683

3. “Targeted Alpha Therapy (TAT) with Single-Domain Antibodies (Nanobodies)”
by Kate Hurley, Meiyun Cao, Haiming Huang and Yi Wang
Cancers 2023, 15(13), 3493; https://doi.org/10.3390/cancers15133493
Available online: https://www.mdpi.com/2072-6694/15/13/3493

4. “Clinical Significance of ABCG2/BCRP Quantified by Fluorescent Nanoparticles in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy”
by Hiroshi Tada, Kohsuke Gonda, Narufumi Kitamura and Takanori Ishida
Cancers 2023, 15(8), 2365; https://doi.org/10.3390/cancers15082365
Available online: https://www.mdpi.com/2072-6694/15/8/2365

5. “Nanotechnology-Based Drug Delivery Approaches of Mangiferin: Promises, Reality and Challenges in Cancer Chemotherapy”
by Muhammad Sarfraz, Abida Khan, Gaber El-Saber Batiha, Muhammad Furqan Akhtar, Ammara Saleem, Basiru Olaitan Ajiboye, Mehnaz Kamal, Abuzer Ali, Nawaf M. Alotaibi, Shams Aaghaz et al.
Cancers 2023, 15(16), 4194; https://doi.org/10.3390/cancers15164194
Available online: https://www.mdpi.com/2072-6694/15/16/4194

6. “Gold Nanoparticles Enhance the Tumor Growth-Suppressing Effects of Cetuximab and Radiotherapy in Head and Neck Cancer In Vitro and In Vivo”
by Takumi Sato, Yasumasa Kakei, Takumi Hasegawa, Masahiko Kashin, Shun Teraoka, Akinobu Yamaguchi, Ryohei Sasaki and Masaya Akashi
Cancers 2023, 15(23), 5697; https://doi.org/10.3390/cancers15235697
Available online: https://www.mdpi.com/2072-6694/15/23/5697

7. “Insights into Gold Nanoparticles Possibilities for Diagnosis and Treatment of the Head and Neck Upper Aerodigestive Tract Cancers”
by Lídia M. Andrade and Guilherme M. J. Costa
Cancers 2023, 15(7), 2080; https://doi.org/10.3390/cancers15072080
Available online: https://www.mdpi.com/2072-6694/15/7/2080

8. “Nanomedicine Strategies for Targeting Tumor Stroma”
by Mei-Chi Su, Susheel Kumar Nethi, Pavan Kumar Dhanyamraju and Swayam Prabha
Cancers 2023, 15(16), 4145; https://doi.org/10.3390/cancers15164145
Available online: https://www.mdpi.com/2072-6694/15/16/4145

9. “E. coli Phagelysate: A Primer to Enhance Nanoparticles and Drug Deliveries in Tumor”
by Ketevan Ghambashidze, Ramaz Chikhladze, Tamar Saladze, P. Jack Hoopes and Fridon Shubitidze
Cancers 2023, 15(8), 2315; https://doi.org/10.3390/cancers15082315
Available online: https://www.mdpi.com/2072-6694/15/8/2315

10. “Anticarcinogenic Potency of EF24: An Overview of Its Pharmacokinetics, Efficacy, Mechanism of Action, and Nanoformulation for Drug Delivery”
by Iliyana Sazdova, Milena Keremidarska-Markova, Daniela Dimitrova, Vadim Mitrokhin, Andre Kamkin, Nikola Hadzi-Petrushev, Jane Bogdanov, Rudolf Schubert, Hristo Gagov, Dimiter Avtanski et al.
Cancers 2023, 15(22), 5478; https://doi.org/10.3390/cancers15225478
Available online: https://www.mdpi.com/2072-6694/15/22/5478

You are invited to view and submit relevant papers to the journal Cancers.

Cancers Editorial Office

21 November 2024
Recruiting Editorial Board Members for Cancers

In order to further enhance the international influence of Cancers (ISSN: 2072-6694) and support the Editorial Board with additional expertise, Cancers is inviting interested and eligible researchers from academia to apply for Editorial Board membership.

Editorial Board Members will hold the position for two years, with the possibility of renewal for a second term.

Application eligibility:

  • Researchers must have completed their doctorate/Ph.D. in the past 10 years (considering exceptions for career interruptions, including medical and family leave);
  • Researchers must have served as the first author/corresponding author on at least five peer-reviewed and published manuscripts in the last five years;
  • Researchers must have published impactful work in the field of oncology;
  • Researchers must currently (at the time of application) hold an associate professor, or professor title in academia;
  • Researchers must be actively engaged in their community (e.g., experienced at presenting at conferences or involved in professional organizations).

Benefits for Editorial Board Members include the following:

  • A certificate of appointment as an Editorial Board Member will be provided;
  • An Editorial Board Member may publish one paper per year, free of charge, in an open access format;
  • The journal will regularly acknowledge those who have participated in the peer review process on the journal’s website;
  • There will be opportunities to participate in or host annual meetings and online seminars organized by the Editor-in-Chief and the Editorial Board Members.

Responsibilities of Editorial Board Members include the following:

  • Pre-screening and making decisions on new submissions related to your research interests;
  • Setting up at least one Special Issue during your term on a topic related to your research interests (or supervising Special Issues related to your research field);
  • Helping to attract suitable expert authors and invite young scholars to join the Topical Advisory Panel;
  • Providing input or feedback regarding journal policies;
  • Helping to promote the journal among your peers or at conferences;
  • Attending Board Meetings to suggest journal development strategies;
  • Reviewing manuscripts.

Applications:

Please fill in the application form here.

Please send the application form and your resume to cancers@mdpi.com with the subject “Cancers Editorial Board Application + Name”.

Application deadline: 15 May 2025.

Selection process:

The initial screening of application materials will be followed by selection by the Editor-in-Chief and Editorial Board Members; an email notification will follow, and thereafter a certificate of appointment will be issued.


Displaying Announcement 131-140 on page 14 of 67.
Back to TopTop